Articles related to HEALTHCARE COSTS

The recent study exploring the Mark Cuban Cost Plus Drug Company’s potential impact on Medicare’s oncology drug spending uncovers significant savings opportunities. Physicians may find interest in this model’s potential to improve access to essential cancer medications through reduced costs, emphasizing a call to examine current overpayment within the Medicare system.

Unravel the intricacies of the shifting cost and usage trends of first-line treatments for IESS, and join the conversation about the future of managing this condition.

A new comprehensive study brings to light the considerable cost disparities between FLACS and PCS, urging opthalmologists to reconsider their preferred surgical procedures for cataract treatment.

Despite the demonstrated benefits of the recommended quadruple therapy for heart failure, its cost-effectiveness is highly sensitive to drug pricing, necessitating more thorough scrutiny and potential policy interventions to ensure equitable patient access.

Treading the line between cost-effectiveness and equity in SCD management, gene therapy presents a paradigm shift. Curious about the economic equilibrium in this new era of treatment? Dive into the latest research insights.

Not surprisingly, given the rate at which new FDA approvals are granted, the majority of clinicians prescribed a newly FDA-approved drug in the previous year, with 20% prescribing at least ten new drugs, according to OBRs Oncology Drug Report 2022. The latter metric demonstrates how quickly the world of cancer care is evolving, which has a number of important implications for oncology practice.